XML 64 R53.htm IDEA: XBRL DOCUMENT
v3.25.2

RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2024 USD ($) | Jun. 30, 2024 EUR (€) | Nov. 30, 2020 | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2025 USD ($) | Jun. 30, 2024 USD ($) | Aug. 31, 2024 USD ($) | Dec. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | May 31, 2022 USD ($) | Nov. 30, 2021 USD ($)
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  | $ 2,050,585 | $ 587,503 | $ 4,424,724 | $ 1,472,801 |  |  |  |  |
Research and consulting agreement | Therapeutics Inc. |  |  |  |  |  |  |  |  |  |  |  |
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  | 348,000 | $ 162,000 | 759,000 | $ 650,000 |  |  |  |  |
Research and consulting agreement | Scleroderma |  |  |  |  |  |  |  |  |  |  |  |
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Total amount of agreement |  |  |  |  |  |  |  |  |  |  | $ 610,000 |
Research and consulting agreement | The School of Pharmacy at UCC |  |  |  |  |  |  |  |  |  |  |  |
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Maximum funding amount | $ 668,000 | € 567,000 |  |  |  |  |  |  |  |  |  |
Commitment period | 2 years 6 months | 2 years 6 months |  |  |  |  |  |  |  |  |  |
Accrued research and development expense |  |  |  | $ 60,000 |  | $ 120,000 |  |  |  |  |  |
Consulting agreements | Netherton Syndrome |  |  |  |  |  |  |  |  |  |  |  |
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Total amount of agreement |  |  |  |  |  |  |  |  |  |  |  | $ 250,000
Consulting agreements | Therapeutics Inc. |  |  |  |  |  |  |  |  |  |  |  |
RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS |  |  |  |  |  |  |  |  |  |  |  |
Initial term |  |  | 3 years |  |  |  |  |  |  |  |  |
Written termination notice period |  |  | 90 days |  |  |  |  |  |  |  |  |
Total amount of agreement |  |  |  |  |  |  |  | $ 3,600,000 | $ 830,000 | $ 4,400,000 |  |

X
- Definition Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development expenses incurred. + References No definition available. + Details
Name: | qnrx_AccruedResearchAndDevelopmentExpense
Namespace Prefix: | qnrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | qnrx_AgreementInitialTerm
Namespace Prefix: | qnrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | qnrx_AgreementWrittenTerminationNotice
Namespace Prefix: | qnrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of fee per consulting or service agreement. + References No definition available. + Details
Name: | qnrx_ConsultingOrServiceAgreementAgreedAmount
Namespace Prefix: | qnrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum liability for the entity in relation to the funding for the research agreement entered into. + References No definition available. + Details
Name: | qnrx_ResearchAgreementMaximumFundingAmount
Namespace Prefix: | qnrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_LongtermPurchaseCommitmentPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=qnrx_TherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=qnrx_SclerodermaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=qnrx_SchoolOfPharmacyAtUccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=qnrx_ConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=qnrx_NethertonSyndromeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |